Changes in Beneficial Ownership · 4
Neuropace, Inc.
NPCENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1782160441.xml
Filing details
- Report period
- 2026-06-19
- Issuer
- NeuroPace Inc
- Issuer CIK
- 0001528287
- Trading symbol
- NPCE
Reporting owner 1
- Name
- Geiger Uri
- Reporting owner CIK
- 0001467361
- Relationship
- Director
- Address
- C/O NEUROPACE, INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-19 | A · Form 4 | 789[F1] | A | 15.63 | 18,537 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 4,432,948 | I | See footnote[F2] |
Table key
- I
- Indirect
Footnotes
- F1
- These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.↩ 1
- F2
- Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.↩ 1
Signature 1
- Signed
- /s/ Leah Akin, Attorney-in-Fact
- Date
- 2026-06-22
Company context
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.